胰岛素增长因子结合蛋白-6和肝脏
Anna Rita Daniela Coda1, Sławomir Kasperczyk2, Michał Dobrakowski3
1C.R.E.A.T.E.-Center for Research and Innovation in Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Cells
|January 9, 2026
概括
胰岛素类生长因子结合蛋白6 (IGFBP-6) 在肝脏健康和疾病中起着复杂的作用. 这篇评论强调了它对肝脏新陈代谢,损伤和癌症的影响,表明它作为诊断和治疗点的潜力.
科学领域:
- 肝脏生物学和疾病
- 内分泌学 在内分泌学.
- 分子信号传递是分子信号传递.
背景情况:
- 胰岛素样生长因子 (IGF) 轴对肝功能至关重要,但个体IGF结合蛋白 (IGFBPs) 的作用尚不清楚.
- IGFBP-6是一种偏爱IGF-II的结合蛋白,通过独立的作用影响IGF的生物可用性和信号传递.
研究的目的:
- 综合IGFBP-6在肝脏生物学和疾病中的现有证据.
- 评估其在肝脏发育,平衡,损伤和癌症中的作用.
- 评估其用于诊断和治疗的翻译潜力.
主要方法:
- 对IGFBP-6表达,调节和功能的实验和临床数据的审查.
- 对IGFBP-6参与规范IGF信号通路 (PI3K-AKT,RAS-MAPK) 的分析.
- 检查IGFBP-6的联系与肝脏疾病,如肥胖症,炎症,纤维化和癌症 (HCC,胆管癌).
主要成果:
- IGFBP-6的表达和处理因肝脏发育,平衡和损伤而有所不同.
- 它调节IGF-II/IGF1R信号传递和下游通路.
- IGFBP-6涉及脂肪酸,炎症,纤维生成和肝癌,显示出瘤抑制和亲迁移效应.
- 与缺氧,Wnt/β-catenin,TGF-β信号传递和免疫微环境的潜在交叉.
结论:
- IGFBP-6是一种细微的肝脏病理生理学调节剂.
- 它作为患者分层和治疗向的生物标志物具有前景.
- 对于标准化测量,细胞类型解析分析和体内研究,需要进一步的研究.
相关概念视频
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Liver Physiology
3.5K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.5K
Cell Specific Gene Expression
16.2K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836


